default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Handok, CMG apply for P1 trial for anticancer treatment candidate

Lee Han-soo  Published 2019.04.05  12:23  Updated 2019.04.05 12:23

공유
default_news_ad2

Handok and CMG Pharmaceutical said they have applied to the Ministry of Food and Drug Safety for starting the phase 1 clinical trials of pan-tropomyosin receptor kinase (TRK) inhibition anticancer treatment candidate.

The two companies are developing the drug alongside the National OncoVenture under the National Cancer Center (NCC). The medicine uses a new mechanism of selectively inhibiting TRK protein, which can develop various cancers such as thyroid, non-small cell lung and colon cancer, and polymorphous glioblastoma.

The company expects that the treatment will help treat cancer patients who have a rearrangement of the TRK gene group suffering from no available treatment.

“We will do our best to develop innovative global anti-cancer drugs by combining our capabilities with CMG Pharmaceutical and the National OncoVenture,” Handok CEO Kim Young-jin said.

CMG Pharmaceutical CEO Lee Joo-hyung said, “We will utilize the experience and infrastructure of CMG Pharmaceutical, Handok’s R&D technology and NCC’s development project team to create a world-class anticancer drug.”

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch